NASDAQ:FGEN - FibroGen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $49.11 +1.80 (+3.80 %) (As of 01/16/2019 07:20 AM ET)Previous Close$47.31Today's Range$47.22 - $49.1752-Week Range$37.27 - $68.55Volume529,992 shsAverage Volume777,220 shsMarket Capitalization$4.02 billionP/E Ratio-28.39Dividend YieldN/ABeta1.67 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California. Receive FGEN News and Ratings via Email Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FGEN Previous Symbol CUSIPN/A Webwww.fibrogen.com Phone415-978-1200Debt Debt-to-Equity Ratio0.20 Current Ratio6.76 Quick Ratio6.76Price-To-Earnings Trailing P/E Ratio-28.39 Forward P/E Ratio-31.68 P/E GrowthN/A Sales & Book Value Annual Sales$125.67 million Price / Sales33.21 Cash FlowN/A Price / Cash FlowN/A Book Value$7.09 per share Price / Book6.93Profitability EPS (Most Recent Fiscal Year)($1.73) Net Income$-126,200,000.00 Net Margins-87.84% Return on Equity-24.59% Return on Assets-14.83%Miscellaneous Employees423 Outstanding Shares84,980,000Market Cap$4.02 billion OptionableOptionable FibroGen (NASDAQ:FGEN) Frequently Asked Questions What is FibroGen's stock symbol? FibroGen trades on the NASDAQ under the ticker symbol "FGEN." How were FibroGen's earnings last quarter? FibroGen Inc (NASDAQ:FGEN) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.15. The biopharmaceutical company earned $29 million during the quarter, compared to analysts' expectations of $36.48 million. FibroGen had a negative return on equity of 24.59% and a negative net margin of 87.84%. FibroGen's quarterly revenue was down 28.6% on a year-over-year basis. View FibroGen's Earnings History. When is FibroGen's next earnings date? FibroGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for FibroGen. What price target have analysts set for FGEN? 3 brokers have issued 1-year target prices for FibroGen's stock. Their forecasts range from $71.00 to $84.00. On average, they expect FibroGen's share price to reach $76.3333 in the next twelve months. This suggests a possible upside of 55.4% from the stock's current price. View Analyst Price Targets for FibroGen. What is the consensus analysts' recommendation for FibroGen? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen. What are Wall Street analysts saying about FibroGen stock? Here are some recent quotes from research analysts about FibroGen stock: 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (1/9/2019) 2. Mizuho analysts commented, "We believe efficacy data is likely to be a non-event in 4Q18. But we believe MACE will be share-moving. We believe roxadustat can achieve superiority vs. epoetin alfa in the DD patient population, given encouraging mortality rate observed in recent studies vs. much higher historical rates with epoetin alfa. In NDD, we believe the bar is higher (comparing to placebo) but showing non-inferiority is possible (more below)." (12/17/2018) Has FibroGen been receiving favorable news coverage? News articles about FGEN stock have been trending positive on Wednesday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FibroGen earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the stock's share price in the immediate future. Who are some of FibroGen's key competitors? Some companies that are related to FibroGen include Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Perrigo (PRGO) and Dr.Reddy's Laboratories (RDY). Who are FibroGen's key executives? FibroGen's management team includes the folowing people: Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)Mr. Pat Cotroneo, Chief Financial Officer (Age 55)Dr. K. Peony Yu, Chief Medical Officer (Age 57)Mr. Julian N. Stern, Sec. (Age 94)Dr. Barry A. Berkowitz, Founder When did FibroGen IPO? (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. How do I buy shares of FibroGen? Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is FibroGen's stock price today? One share of FGEN stock can currently be purchased for approximately $49.11. How big of a company is FibroGen? FibroGen has a market capitalization of $4.02 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe. What is FibroGen's official website? The official website for FibroGen is http://www.fibrogen.com. How can I contact FibroGen? FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected] MarketBeat Community Rating for FibroGen (NASDAQ FGEN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 215 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 419MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: What is an Initial Public Offering (IPO)?